Form 4: OrbiMed Advisors Sells 3,571,428 Shares of Compass Therapeutics

OrbiMed Advisors LLC reports the disposition of 3,571,428 shares of Compass Therapeutics, Inc. at a price of $1.59 per share.

Summary

• OrbiMed Advisors LLC, along with related entities OrbiMed Capital GP VI LLC and OrbiMed Genesis GP LLC, filed a Form 4 regarding changes in beneficial ownership of Compass Therapeutics, Inc. (CMPX) stock.
• On April 9, 2025, OrbiMed Advisors disposed of 3,571,428 shares of Common Stock at a price of $1.59 per share.
• Following the transaction, OrbiMed entities still indirectly own 15,219,994 shares of Compass Therapeutics.
• The shares are held by OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments V KA, LP.
• OrbiMed Advisors exercises investment and voting power through a management committee.
• Carl L. Gordon, a member of OrbiMed Advisors, serves on the Issuer's board of directors.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the filing itself is a standard regulatory requirement, the sale of a significant number of shares by a major holder like OrbiMed could be perceived negatively by the market.

Negatives

• OrbiMed Advisors disposed of a significant number of shares (3,571,428) which could be interpreted negatively by the market.

Risks

• The sale of a large block of shares by a major shareholder like OrbiMed could create downward pressure on the stock price.
• The market may interpret the sale as a lack of confidence in the future prospects of Compass Therapeutics.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of its pecuniary interest therein, if any.
• This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders and major shareholders. OrbiMed is a well-known healthcare investment firm, so their transactions are closely watched by the market.

Comparison to Industry Standards

• It's common for large institutional investors like OrbiMed to periodically adjust their holdings in portfolio companies.
• The impact of this sale on Compass Therapeutics' stock price will depend on market sentiment and the overall performance of the biotechnology sector.
• Comparable transactions involving similar-sized biotech companies and institutional investors could provide a benchmark for assessing the significance of this sale.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's sale, potentially impacting the stock price.
• The sale could influence investor confidence in Compass Therapeutics.

Key Dates

Keywords

OrbiMed Advisors, Compass Therapeutics, CMPX, beneficial ownership, Form 4, stock sale, investment